Men who are homozygotic for the TCF7L2‐rs12255372 T allele have a high relative risk for more aggressive prostate cancer, defined by a high Gleason score (OR = 1.7; 95% CI = 1.0–2.8) or by a high regional and/or distal stage (OR = 1.7; 95% CI = 1.1–2.6) (Agalliu et al., 2008). The gene discussed is TCF7L2; the disease is prostate carcinoma.